Welcome to our dedicated page for Precision Biosciences SEC filings (Ticker: DTIL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Precision BioSciences, Inc. filings document regulatory disclosures for a clinical-stage gene editing company built around the ARCUS platform and in vivo therapeutic candidates. Recent Forms 8-K furnish operating results, financial-condition updates, business presentations, and Regulation FD materials covering PBGENE-HBV in chronic hepatitis B and PBGENE-DMD in Duchenne muscular dystrophy, including IND-related and clinical-development disclosures.
The company’s proxy materials address board and stockholder meeting matters, executive compensation, equity plans, and governance proposals. Other filing categories cover material agreements, shareholder voting matters, capital-structure disclosures, inducement awards, and forward-looking risk language tied to clinical development, financing capacity, regulatory review, and public-company reporting.
Precision BioSciences (DTIL) filed its Q3 2025 10-Q, reporting continued investment in ARCUS gene editing programs and a wider net loss. Quarterly revenue was $13 thousand, reflecting lower billable work under the Novartis collaboration. Operating loss was $20.7 million and net loss was $21.8 million. Cash and cash equivalents were $44.9 million, with restricted cash of $26.3 million; total cash, cash equivalents and restricted cash were $71.2 million as of September 30, 2025.
The balance sheet shows total liabilities of $76.9 million, including a $22.5 million term loan and $26.2 million in deferred revenue, and stockholders’ equity of $16.6 million. A warrant liability was $4.0 million. Shares outstanding were 12,082,665 as of September 30, 2025, and 13,256,751 as of October 29, 2025.
PBGENE-HBV advanced with Cohort 3 dosing in the ELIMINATE-B trial, while PBGENE-DMD moved toward an anticipated U.S. IND filing by year-end 2025 after receiving Rare Pediatric Disease and Orphan Drug designations. Subsequent events included an $8.0 million milestone from Imugene on October 31, 2025 (paid as $3.0 million cash and $5.0 million stock) and Novartis’ notice to terminate the collaboration effective January 30, 2026.
Precision BioSciences, Inc. furnished an update on its financials, announcing results for the quarter ended September 30, 2025. The company disclosed the information under Item 2.02 and provided the full details via a press release.
The press release is included as Exhibit 99.1, which is incorporated by reference. The company’s common stock trades on the Nasdaq Capital Market under the symbol DTIL.
Stanley R. Frankel, a director of Precision BioSciences, Inc. (DTIL), purchased 2,700 shares of the company's common stock on 09/26/2025 at a reported price of $4.97 per share. After this transaction he beneficially owned 16,778 shares. The Form 4 was signed on 09/30/2025 by an attorney-in-fact, Dario Scimeca. The filing identifies Frankel's address as c/o Precision BioSciences in Durham, North Carolina, and indicates the report was filed by one reporting person. No derivative transactions, amendments, or other securities activity are reported on this Form 4.
Precision BioSciences director Melinda Brown made an open-market purchase of company stock on 09/22/2025. She acquired 1,400 shares of Common Stock at a price of $4.89 per share, increasing her direct beneficial ownership to 21,965 shares following the transaction. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Brown on 09/24/2025. The filing identifies Ms. Brown as a director and indicates this Form 4 was filed by one reporting person. No derivative transactions or other securities classes are reported on this form.
Precision BioSciences director Melinda Brown made an open-market purchase of company stock on 09/22/2025. She acquired 1,400 shares of Common Stock at a price of $4.89 per share, increasing her direct beneficial ownership to 21,965 shares following the transaction. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Brown on 09/24/2025. The filing identifies Ms. Brown as a director and indicates this Form 4 was filed by one reporting person. No derivative transactions or other securities classes are reported on this form.
Precision BioSciences, Inc. updated employment agreements for its key Section 16 officers, including the CEO, CFO, General Counsel, and Chief Research Officer, to support executive retention.
The amended agreements align terms with each executive’s current base salary and target bonus, change cash severance to lump-sum payments, and add protections for terminations without cause in connection with a defined change in control or restructuring event. They also provide for additional expense coverage.
To secure these obligations, the company established escrow arrangements with JPMorgan Chase Bank, N.A., funding severance and expense amounts in dedicated accounts. Interest on the escrowed funds and any unused balances revert to Precision BioSciences.
Precision BioSciences Schedule 13G/A shows that Readout-affiliated entities and Matthew Smith reported collective beneficial ownership of up to 1,119,311 shares of the issuer's common stock as of June 30, 2025, representing approximately 9.4% of the outstanding class. The filing breaks ownership across Readout Capital, Readout Capital GP, ROC Holdings SPV II, Readout Holdings GP and Matthew Smith, and discloses that ROC SPV II directly held 686,437 shares plus warrants exercisable into 220,000 shares. Readout Capital also manages a separate account holding 200,000 shares under an investment management agreement. Signatures certify the disclosures.
Schedule 13G summary: Bleichroeder LP, Bleichroeder Holdings LLC and Andrew Gundlach report beneficial ownership of 1,075,000 common shares of Precision BioSciences, representing 9.69% of the outstanding common stock. The filing shows the reporting persons hold sole voting and sole dispositive power over these shares and report no shared voting or dispositive power. Bleichroeder LP is identified as an investment adviser and is deemed to beneficially own the shares as adviser to various clients, while those clients retain the right to dividends and sale proceeds. The filing is submitted on Schedule 13G with exhibits for an agreement among reporting persons and subsidiary information.